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Mammalian tissues react to damage by activating the highly specialized response of wound
healing. Acute inflammation is the first and fastest mechanism activated in the damaged area, as
a fundamental protective and transitional response with the purpose of progressive activation of
endogenous tissue cells for reparative activities (Reinke and Sorg, 2012; Sattler, 2017). The balance
between degree of damage, potency of the subsequent inflammatory wave, and the regenerative
ability of resident cells determines the extent by which tissues can accomplish regeneration (for
low-grade damage or in highly regenerative tissues, such as the liver) or fibrotic repair (for
extensive damage or in poorly regenerative tissues, such as the myocardium). Persistent damage,
complications, or repeated insults, can sustain the continuous or aberrant activation of repair
pathways, leading to chronic inflammation and progressive tissue fibrosis (Sattler et al., 2017;
Henderson et al., 2020). Despite the evolutionary advantage conferred to mammals by scarring
as a rapid repair mechanism, biological and mechanical features of the original tissue architecture
are disrupted in the scar area (Forbes and Rosenthal, 2014). Over time, chronic fibrosis thus leads
to tissue adverse remodeling and impaired function. Persistent inflammation and fibrosis play a
major role in a wide range of diseases, accounting for an increasingly large fraction of morbidity
and mortality worldwide (Henderson et al., 2020).
While recent advances have unveiled many environmental and genetic causes of fibrotic
disorders (Spagnolo et al., 2014; Cutting, 2015), a better understanding of both ubiquitous and
tissue-specific regulatory pathways, and cellular dynamics could help to design new targeted
therapies, and even to identify the etiology of idiopathic disease.
Within this Research Topic, we have gathered several contributions on the cellular and
molecular mediators of fibrosis, and the intertwined pathophysiological role of fibrosis
and inflammation in different tissues and diseases, with particular emphasis on renal and
cardiac fibrosis.

CELLULAR AND MOLECULAR MEDIATORS OF FIBROSIS
Fibroblasts are increasingly regarded as a complex cell type. In fact, it has become clear that multiple
phenotypes and functional states can be identified in the stroma of organs, with significantly
different functions (Forte et al., 2018, 2020; Farbehi et al., 2019; Muhl et al., 2020; Mohenska et al.,
2021; Plikus et al., 2021). Here, Huang et al. contributed a critical review on the association between
specific fibroblast genes with biological and functional definitions, as this link seems to be subtle and
blurred in many different tissues. The complex topic of fibroblast phenotypes is further complicated
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to TGF-β1 through AK strain Transforming (AKT) and
Extracellular signal-Regulated Kinase (ERK), particularly by
mediating proliferation and migration of activated fibroblasts.
Pandita et al. contributed a study on the relationship
between mitochondrial voltage, as an indicator of oxidative
phosphorylation levels, and the progression of fibrosis in
the liver. They showed mechanistic association between the
upregulation of mitochondrial electron transport chain enzymes,
oxygen consumption, and the activation of the AMP-activated
protein Kinase (AMPK) pathway, providing an interesting link
between metabolism, hepatic insult responses, and early signs of
fibrosis in the liver.

under pro-fibrotic conditions by the trans-differentiation
of endothelial cells into myofibroblasts by endothelial-tomesenchymal transition—End-MT (Forte et al., 2017; Hulshoff
et al., 2019). Giordo et al. contributed a review on the interesting
relationship between non-coding RNAs, oxidative stress, and
End-MT in fibrosis complications affecting the retina, kidneys,
heart, and vessels during diabetes progression.
However, fibroblasts are not the only stromal cell type
of interest for tissue fibrosis and repair (Forte et al., 2018;
Farbehi et al., 2019). Tissue resident mesenchymal cells are
described in multiple organs, where they are involved in
homeostasis and disease (Lemos and Duffield, 2018). Theret
et al. reviewed the literature about fibro-adipogenic progenitors
in muscle integrity, extracellular matrix (ECM) deposition, and
in response to injury, also analyzing their contribution to the
pool of activated fibroblasts in muscle fibrosis and degenerative
conditions. On a different perspective, cardiac cell therapy with
mesenchymal cells holds promise for the treatment of myocardial
infarction (Peruzzi et al., 2015; Pagano et al., 2019; Guo et al.,
2020). Tang et al. described that thymosin-β4 overexpression
in bone-marrow mesenchymal cells significantly increases their
therapeutic potential on cardiac function in a rat model. This
effect is mediated, among others, by a reduction of the scar area
and decrease in collagen deposition in the infarcted myocardium,
and by increased activation of the Hypoxia-Inducible Factor
1-alpha (HIF-1α) pathway.
One hallmark of fibrosis in multiple organs is excessive
ECM deposition (Herrera et al., 2018). Leong et al. reviewed
the literature about the key enzymes of ECM remodeling,
matrix metalloproteinases (MMPs) and their tissue inhibitors, in
systemic sclerosis, on the quest for novel therapeutic targets to
treat tissue stiffening and loss of function. MMPs also regulate
the bioavailability of humoral factors. Adu-Amankwaah et al.
contributed a review on the multiple roles of A Disintegrin
And Metalloproteinase 17 (ADAM17), which is emerging as
a core regulatory factor in inflammation and fibrosis. In fact,
ADAM17 can activate multiple cytokines and pro-fibrotic factors
(e.g., Tumor Necrosis Factor alpha—TNFα, soluble InterLeukin
6 Receptor—sIL-6R, Amphiregulin—AREG) in cardiac fibrosis
and in catecholamine stress during heart failure progression,
highlighting potential therapeutic targets. Moreover, cell–ECM
interaction and crosstalk are responsible for the effects of
tissue stiffening in fibrotic diseases on both parenchymal and
stromal cells. Key transducers of ECM stiffening are integrins,
and Xu et al. studied the integrin family expression in skin
tissue of systemic sclerosis patients from the Gene Expression
Omnibus-GEO database, describing the upregulation of several
integrins involved in ECM turnover, leucocyte extravasation,
Transforming Growth Factor beta 1 (TGF-β1) signaling, and
immune cell activation. These results highlight the strong
relationship between ECM, resident cells, and immune cells in
tissue remodeling and fibrosis.
Fuentes-Calvo et al. provided another contribution to the
understanding of molecular mechanisms of fibroblast activation,
by describing the role of RAt Sarcoma virus protein (RAS)
activator Son Of Sevenless 1 (SOS1) in murine embryonic
fibroblasts. Their results show that SOS1 mediates the response
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CARDIAC FIBROSIS
Myocardial fibrosis is involved in multiple cardiac diseases,
and is fueled by continuous cardiomyocyte death, inflammatory
cell recruitment, and direct activation of resident fibroblasts
(Schirone et al., 2017; Forte et al., 2018, 2020; Panahi et al.,
2018). Multiple signaling pathways are known to control
fibroblast behavior (Plikus et al., 2021). Xie et al. investigated
the role of High-Mobility Group A1 protein (HMGA1) in
cardiac fibroblast activation, showing how it is overexpressed
in an isoproterenol-treated mouse model, and that it mediates
fibrosis via FOrkhead boX protein O1 (FOXO1). Conversely,
its knockdown inhibits fibroblast responses to TGF-β1, thus
identifying a novel molecular target for possible anti-fibrotic
treatments in the heart.
Platelet-derived growth factors (PDGFs) are important
mediators of inflammation, angiogenesis, and fibroblasts
activation, and represent possible therapeutic targets against
myocardial remodeling. Kalra et al. reviewed the literature
concerning PDGF signaling mechanisms and beneficial effects
in cardiac injury, highlighting the potentials and pitfalls for
translational research. Concerning the identification of specific
markers for myocardial injury, Cimini et al. contributed a
review on podoplanin, a novel marker upregulated in multiple
cell types after infarction. During homeostasis, podoplanin is
expressed by lymphatic endothelial cells, but after injury many
cell types upregulate its expression, including fibroblasts and
hematopoietic cells. The authors provide an overview of several
studies evidencing a wide range of possible interactions mediated
by podoplanin among different cell compartments.
Concerning novel synergistic therapeutic approaches for the
heart, Hou et al. studied how estradiol supplementation in
rats during isoproterenol-induced stress can prevent cardiac
dysfunction and maladaptive myocardial hypertrophy. In
particular, these effects were shown to be mediated by β2adrenoceptors and the resolution of inflammation due to an
increased anti-inflammatory macrophage phenotype, evidencing
an interesting endocrine/immune-modulatory circuit in the
heart. Adzika et al. studied a possible combined therapy with
forskolin (i.e., an adenylyl cyclase activator able to modulate
cardiac and inflammatory responses) and amlexanox [i.e., a G
protein-coupled Receptor Kinase 5 (GRK5) inhibitor of adaptive
immune responses] to prevent pathological cardiac hypertrophy
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transition and tubular cells trans-differentiation, proposing
another novel therapeutic strategy against renal fibrosis. In this
regard, Wu et al. identified the circular RNA circHIPK3 as a
possible novel therapeutic target for renal fibrosis. They found
that circHIPK3 is upregulated in a mouse model of induced renal
fibrosis. The study demonstrated that circHIPK3 reduces the
activity of miRNA-30a, a known negative regulator of profibrotic
genes, including TGF-β1, fibronectin, and collagen 1. CircHIPK3
sequesters miRNA-30a in the cytoplasm of tubular epithelial cells
by directly binding to it, and this promotes the expression of
profibrotic genes and the progression of renal fibrosis.
Inflammation and fibrosis are closely connected to alterations
in the composition and properties of the ECM (Pesce et al.,
2017; Herrera et al., 2018). As for the heart, the mechanisms by
which ECM stiffening may aggravate renal fibrosis are still under
investigation. Fu et al. reported that enhanced substrate stiffness
can activate mesangial cells toward fibrotic features through the
Piezo1, p38MAPK, and Yes-Associated Protein (YAP) pathway.
They showed both in vitro and in vivo in a unilateral ureteral
occlusion model in mice, that Piezo1 knockdown can counteract
this activation, as well as fibrosis progression, suggesting a novel
mechanosensing-based strategy against renal fibrosis. Another
contribution on mechanosensing is focused on diabetes and the
vasculature. Diabetes represents the starting condition triggering
multiple organ damage (Frati et al., 2017; Cosentino et al.,
2020). Ortillon et al. reported that YAP signaling is activated
in vitro in endothelial cells by exposure to high glucose, and in
vivo in the vessels of db/db mice. Its activation is potentiated
under flow stress, evidencing a novel role in enhancing diabetic
inflammatory signals in the vasculature.

in mice. This treatment was effective at preventing left ventricular
systolic dysfunction during isoproterenol-induced chronic stress
by attenuating maladaptive myocardial hypertrophy, fibrosis, and
inflammatory responses. Finally, Yang et al. studied how Receptor
Interacting Protein kinase 2 (RIP2) is upregulated in failing
hearts, both in human patient samples and murine models of
aortic banding, as well as in angiotensin II-treated neonatal rat
cardiomyocytes. RIP2 overexpression indeed aggravates cardiac
remodeling through phosphorylation of targets such as TGFβActivated Kinase 1 (TAK1), p38 mitogen-activated protein
kinase (p38MAPK), and Jun N-terminal Kinases (JNK1/2). Thus,
inhibiting RIP2 or its targets may inhibit cardiac remodeling,
representing another potential preventive strategy in cardiology.

RENAL FIBROSIS
Fibrosis and inflammation are also significantly involved in
kidney pathophysiology and progressive functional impairment,
particularly in chronic kidney disease (Panizo et al., 2021). Cao
et al. reviewed the literature on the role of lymphocytes in
kidney fibrosis and disease, discussing how different subsets
play different and antagonistic roles: in fact, T-helper cells
and innate-like lymphocytes exert mainly pathogenic roles,
while CD4− /CD8− double negative and T-reg cells are
considered protective. Further elucidation of the different roles of
lymphocytes in renal injury and fibrosis may guide the discovery
of novel specific therapeutics. Instead, Fang et al. focused their
attention on diabetic kidney disease and the gut microbiota: they
show that the microbiota metabolite trimethylamine N-oxide
accelerates kidney dysfunction by activating the inflammasome
and releasing pro-inflammatory cytokines in a high-fat diet/lowdose streptozotocin-induced rat model of diabetes, providing
new perspectives on the pathogenesis and potential treatment of
diabetic kidney disease.
Zhang et al. reported a novel protective mechanism of
the traditional Chinese medicine compound called Qishen
Yiqi Dripping Pill on diabetic nephropathy. In a high-fat
diet/streptozotocin rat model of diabetes this treatment yielded
improved kidney function and reduced fibrosis; moreover,
they evidenced inhibition of the Wingless-iNTegration—
Wnt/β-catenin and the TGF-β/Smad2 signaling pathways,
thus highlighting a potential direct effect on activation of
tissue fibrosis. Regarding other related mechanisms of injury,
Jia et al. described that attenuation of DNA damage and
senescence in tubular cells by the NAD+ precursor nicotinamide
mononucleotide (NMN) may exert a protective effect against
acute kidney injury; they confirmed this therapeutic and
preventive potential both in vitro and in vivo, in an ischemiareperfusion injury mouse model showing cell protection and
reduced inflammation.
Concerning direct interference with mechanisms of fibroblast
activation and fibrosis, Xie et al. showed that exogenous
transfection of the Bone Morphogenetic Protein binding
Endothelial Regulator (BMPER) in a mouse model of renal
fibrosis blocks fundamental mechanisms of fibroblast activation
mediated by TGF-β1, such as epithelial-to-mesenchymal
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FIBROSIS MODELING AND DRUG
TESTING
Research into novel treatments targeting fibrosis greatly benefits
from advancements in relevant and reproducible animal models,
as well as in vitro systems with increasing physiological relevance
(Lagares and Hinz, 2021). As part of this article collection, Palano
et al. summarized and discussed available assays to study cardiac
fibrosis, with emphasis on the most recent innovations in multicellular 3D cultures and computational methods for scaling up
and boosting preclinical and translational research. Bao et al.,
on the other hand, focused their review on the analysis and
comparison of different animal models of liver fibrosis and their
ability to mimic different etiologies and pathogenic mechanisms.
They also presented the most recent advances in liver organoid
cultures as relevant alternatives to in vivo testing.
Looking for novel anti-inflammatory and immunosuppressive
therapeutic options, Pryimak et al. reviewed the growing body
of literature suggesting that cannabinoids and Cannabis sativa
extracts may exert anti-fibrotic effects at multiple levels and
in multiple organs. In this review, the authors suggest the
introduction of cannabinoids for the prevention and treatment of
fibrosis as a versatile and widely applicable therapeutic strategy.
In conclusion, the present Research Topic has collected a
significant amount of novel and interconnected contributions
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on the multifaceted roles of inflammation and fibrosis in
different tissues and diseases. The increasing knowledge in
the field is paving the way towards multi-target therapeutic
strategies against chronic diseases, as well as to novel
treatments adaptable to various organs sharing similar
pathogenetic pathways.
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